Onlyglim-MV 1 Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. This sustained-release tablet contains Glimepiride (1 mg), Metformin (500 mg), and Voglibose (0.2 mg), each contributing distinct mechanisms to manage hyperglycemia. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby enhancing endogenous insulin levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which facilitates increased glucose uptake by muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, reducing postprandial blood glucose spikes. The sustained-release formulation ensures a gradual release of active ingredients, promoting stable plasma concentrations and minimizing gastrointestinal side effects commonly associated with immediate-release formulations. Onlyglim-MV 1 Tablet SR is indicated as an adjunct to diet and exercise for better glycemic control in patients inadequately controlled on monotherapy or dual therapy. It should be used under medical supervision with periodic monitoring of blood glucose and renal function. Caution is advised in patients with hepatic or renal impairment, and contraindications include diabetic ketoacidosis and hypersensitivity to any component. Adherence to prescribed dosage and lifestyle modifications is essential for optimal therapeutic outcomes.